Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Syros Pharmaceuticals (NQ: SYRS )

0.2677 -0.0255 (-8.70%)
Streaming Delayed Price Updated: 11:54 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Syros Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
S&P 500 Tops 6,000; Rumble Shares Slide After Q3 Results
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Jumps Over 150 Points; CyberArk Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default
Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, impacting future trial plans. 
Via Benzinga
US Stocks Mixed; Inflation Rate Increases In October
Via Benzinga
Topics Economy
Exposures Interest Rates
Why Rocket Lab Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update
From Syros Pharmaceuticals
Via Business Wire
Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
From Syros Pharmaceuticals
Via Business Wire
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
From Syros Pharmaceuticals
Via Business Wire
SYRS Investors Have Opportunity to Join Syros Pharmaceuticals, Inc. Securities Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Crude Oil Down 2%; Paysafe Shares Surge After Q2 Results
Via Benzinga
Exposures Fossil Fuels
S&P 500 Gains 1%; Home Depot Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
Nasdaq Surges 200 Points; US Producer Prices Increase 0.1% In July
Via Benzinga
Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome
Syros Pharmaceuticals announces discontinuing enrollment in the SELECT-AML-1 Phase 2 trial due to the low probability of demonstrating superiority. The trial evaluated tamibarotene with venetoclax and... 
Via Benzinga
Why Is Syros Pharmaceuticals (SYRS) Stock Down 62% Today?
Syros Pharmaceuticals stock is down on Tuesday as SYRS investors react to the company discontinuing enrollment for a clinical trial. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to dive into the biggest pre-market stock movers for Tuesday as we check out all of the hottest news moving shares this morning. 
Via InvestorPlace
Why Rumble Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update
From Syros Pharmaceuticals
Via Business Wire
Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
From Syros Pharmaceuticals
Via Business Wire
Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression
From Syros Pharmaceuticals
Via Business Wire
SYRS Stock Earnings: Syros Pharmaceuticals Beats EPS for Q1 2024
SYRS stock results show that Syros Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update
From Syros Pharmaceuticals
Via Business Wire
Syros to Participate in Upcoming Investor Conferences
From Syros Pharmaceuticals
Via Business Wire
Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
From Syros Pharmaceuticals
Via Business Wire
Crude Oil Down Over 1%; Cognyte Software Shares Plummet
U.S. stocks traded lower toward the end of trading, with the S&P 500 falling around 0.4% on Tuesday. The Dow traded down 0.46% to 38,713.72 while the NASDAQ fell 0.24% to 16,215.32. The S&P 500 also... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.